At Mikrobiomik, we develop innovative biological therapies based on gut microbiota transplantation (TMF) to treat serious diseases associated with alterations in the human microbiome.
MBK-01 has been authorized as a biological therapy in oral capsules using FSPIM® (Full Spectrum Purified Intestinal Microbiota) technology to treat recurrent Clostridioides difficile infection (CDI).
We are promoting a new therapeutic approach based on the gut microbiota. In addition to our EUTEGRA therapy (MBK-01), authorised for Clostridioides difficile infection, we are continuing to expand the clinical potential of MBK-01.
Our pipeline includes two ongoing trials, a Phase II study for recurrent acute diverticulitis and a Phase III trial for decompensated liver cirrhosis, exploring new applications for diseases with unmet medical needs.
Final results presentation: Juan Barrero de la Rubia – Project Controller at SERMES CRO
Discussion – Dr. Javier Cobo Reinoso – Clinical trial Cordinator – Ramón y Cajal Hospital
About compassionate use case, (ELA patient): Dra. Maria Varela Cerdeira- La Paz Hospital
We collaborate with various partners. Without them our development would not be possible.
Find out about the latest news.
Mikrobiomik has obtained approval for EUTEGRA (MBK-01) as the first gut microbiota-based biological therapy authorised in Spain
Mikrobiomik is set to launch Spain’s first human microbiome therapy in 2026
MBK-01 demonstrates its clinical impact against Clostridioides difficile infection
First patient for phase III trial in decompensated liver cirrhosis
Recurrent Diverticulitis: too much main, too few answers
Half humans, half microbes
What happens when we overuse antibiotics?
Compassionate Use Programme
